Xspray Pharma AB
http://xspraypharma.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xspray Pharma AB
Keeping Track: Immunocore Wins Nod For First T-Cell Receptor Therapeutic; Veklury And Nucala Expand Settings Of Use; Merck & Co. Strikes Out In Chronic Cough
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'
Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.
Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'
Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.
Deals Shaping The Medical Industry, May 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.
Company Information
- Other Names / Subsidiaries
-
- Xspray Microparticles AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice